oleclumab,durvalumab
astrazeneca
['oleclumab', 'imfinzi', 'bcsm', 'synergy', 'breast']
the combination of oleclumab with imfinzi and chemo did not improve clinical outcomes for patients with advanced triple-negative breast cancer, according to #synergy clinical trial data as presented by from at #esmo2022. #bcsm 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.